Refine Your Results

Click below to filter your search results

"Medications or Drugs"Undo
"Neonatal or Infant"Undo
"Guidelines"Undo

Search Results

Return to List
Results 1–5 of 5
Sort By: Relevance | Date | Title
1.

Antenatal Corticosteroid Therapy for Fetal Maturation

Committee Opinion Number 677, October 2016

ABSTRACT Corticosteroid administration before anticipated preterm birth is one of the most important antenatal therapies available to improve newborn outcomes A single course of corticosteroids is recommended for pregnant women between 24 07 weeks and 33 67 weeks of gestation including for those w...

October 2016

PDF Format
2.

Magnesium Sulfate Use in Obstetrics

Committee Opinion Number 652, January 2016

(Reaffirmed 2016. Replaces Committee Opinion Number 573, September 2013)

ABSTRACT The US Food and Drug Administration advises against the use of magnesium sulfate injections for more than 57 days to stop preterm labor in pregnant women Based on this the drug classification was changed from Category A to Category D and the labeling was changed to include this new warnin...

January 2016

PDF Format
3.

Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period

Committee Opinion Number 623, February 2015

(Reaffirmed 2016. Replaces Committee Opinion Number 514, December 2011)

ABSTRACT Acuteonset severe systolic hypertension severe diastolic hypertension or both can occur in pregnant women or women in the postpartum period Introducing standardized evidencebased clinical guidelines for the management of patients with preeclampsia and eclampsia has been demonstrated to re...

February 2015

PDF Format
4.

Prevention of Early-Onset Group B Streptococcal Disease in Newborns

Committee Opinion Number 485, April 2011

(Replaces No. 279, December 2002, Reaffirmed 2015)

ABSTRACT In 2010 the Centers for Disease Control and Prevention revised its guidelines for the prevention of perinatal group B streptococcal disease Although universal screening at 3537 weeks of gestation and intrapartum antibiotic prophylaxis continue to be the basis of the prevention strategy th...

April 2011

PDF Format
5.

Magnesium Sulfate Before Anticipated Preterm Birth for Neuroprotection

Committee Opinion Number 455, March 2010

Reaffirmed 2015

Abstract Numerous large clinical studies have evaluated the evidence regarding magnesium sulfate neuroprotection and preterm births The Committee on Obstetric Practice and the Society for MaternalFetal Medicine recognize that none of the individual studies found a benefit with regard to their prim...

March 2010

PDF Format

American Congress of Obstetricians and Gynecologists
409 12th Street SW, Washington, DC  20024-2188 | Mailing Address: PO Box 70620, Washington, DC 20024-9998